Open AccessPHARMACOTHERAPY OF SYSTEMIC AUTOIMMUNE DISEASES IN CONDITIONS OF THE COVID-19 PANDEMIC: INNOVATIVE EXPERIMENTAL STUDY
Author(s) -
Ihor Hayduchok
Publication year - 2021
Publication title -
science review
Language(s) - English
Resource type - Journals
eISSN - 2544-9443
pISSN - 2544-9346
DOI - 10.31435/rsglobal_sr/30072021/7619
Subject(s) - pandemic , pharmacotherapy , medicine , pharmacy , covid-19 , drug , intensive care medicine , pharmacology , family medicine , disease , infectious disease (medical specialty)
The article presents the results of an innovative experimental study of pharmacotherapy of systemic autoimmune diseases in a pandemic of coronavirus infection is a timely and socially oriented way. The methodology of conducting a content analysis based on the theoretical principles of pharmaceutical and medical law and its components. Author used the method of drug selection developed by the Department of Medical and Pharmaceutical Law, General and Clinical Pharmacy of the Kharkiv Medical Academy of Postgraduate Education. Content analysis was performed by dosage forms by grouping them using the Sturgess formula, followed by the construction of discrete series of variations and distribution polygon. Received data made possible to state, that in some circumstances, doctors have a choice of both drugs and dosage forms. However, the data obtained show a lack of balance between supply and demand for patients and physicians. The analysis allows to obtain a complete description of the balance of "supply and demand" between the range and types of dosage forms of drugs INN Silymarin ATC code A05BA03, that approved for use.